A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
This study is testing a new experimental drug called AZD1390 alongside radiation therapy for people with brain tumors. Researchers want to see if this combination is safe and how well the body handles the treatment, which could help create more effective options for brain cancer in the future.
This trial is for adults diagnosed with glioblastoma or other tumors that have spread to the brain. You must be able to manage your daily activities and have a previous sample of your tumor tissue available for the researchers to study.
Participants will receive the experimental drug, AZD1390, in combination with radiation therapy to help stop cancer cells from repairing themselves. You will undergo regular check-ups, including MRI scans, to help the medical team monitor your health and how the treatment is working.
The study is currently recruiting patients at medical centers in Boston, Massachusetts, and New York, New York. You can talk to your doctor or the study team to see if one of these locations is right for you.
- 1This is a Phase 1 study, meaning it is the first time this drug combination is being tested in humans.
- 2The study drug works by preventing cancer cells from repairing their own DNA after radiation.
- 3Participants must meet specific health criteria, such as no history of seizures or recent stroke, to ensure safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.